Black Diamond Therapeutics (BDTX) Earnings Date & Reports

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

BDTX is expected to report earnings to fall 127.30% to -26 cents per share on August 12

Black Diamond Therapeutics BDTX Stock Earnings Reports

Q2'25

Est.

$-0.27

Q1'25

Beat

by $0.93

Q4'24

Beat

by $0.07

Q3'24

Beat

by $0.09

Q2'24

Beat

by $0.03

The last earnings report on May 13 showed earnings per share of 98 cents, beating the estimate of 5 cents. With 6.07M shares outstanding, the current market capitalization sits at 133.63M.

View a ticker or compare two or three

Compare

BDTX